EQL EQL Pharma AB (publ)
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers prescription drugs, including hospital products. EQL Pharma AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About EQL Pharma (STO: EQL)
›
EQL Pharma (STO: EQL) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 65 employees.
The shares were at 22.70 SEK on 19 November 2026, down 56.5% over 52 weeks. Its 52-week range is 17.38 SEK to 67.50 SEK: the price is 66.4% below the high and 30.6% above the low.
Its market capitalisation is 670.32M SEK.
EQL Pharma reports return on equity of 4.7%, an operating margin of 6.5% and revenue up 82.0% year over year.
Its debt exceeds its cash by 400.13M SEK, a debt-to-equity ratio of 1.72. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock; their mean price target of 45.00 SEK is 98.2% above the current price.